Editas Medicine Investor Relations Material
Latest events
Q4 2023
Editas Medicine
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Editas Medicine Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Collaboration and other research and development revenues
Expenses by
Financials
Editas Medicine, a genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company seeks to address the fundamental flaws in existing approaches to genetic and infectious diseases by developing TALEN and CRISPR genome editing systems that function more efficiently than existing technologies. It has invented lymphocyte-directed gene therapy that uses CRISPR/Cas9 technology to manufacture a novel endonuclease. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Key slides for Editas Medicine Inc
Corporate Presentation
Editas Medicine Inc
Corporate Presentation
Editas Medicine Inc
Latest articles
Kevin Plank and the Rise of Under Armour
Dive into the story of Under Armour and its founder Kevin Plank, highlighting both successes and mistakes.
30 Apr 2024
Sergey Brin's Role in Shaping the Tech World
Explore Sergei Brin's journey from a Moscow immigrant to co-founding Google, detailing key developments and Alphabet's creation.
29 Apr 2024
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States